Differential pathogenetic mechanisms of mutations in helix 2 and helix 6 of rhodopsin.
BRET
CSNB
GPCR
Molecular simulations
Visual arrestin
mini G protein
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
24
07
2024
revised:
20
08
2024
accepted:
24
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Variants in rhodopsin (RHO) have been linked to autosomal dominant congenital stationary night blindness (adCSNB), which affects the ability to see in dim light, and the pathogenetic mechanism is still not well understood. In this study we report two novel RHO variants found in adCSNB families, p.W265R and p.A269V, that map in the sixth transmembrane domain of RHO protein. We applied in silico molecular simulation and in vitro biochemical and molecular studies to characterize the two new variants and compare the molecular determinants to two previously characterized adCSNB variants, p.G90D and p.T94I, that map in the second transmembrane domain of the RHO protein. We demonstrate that W265R and A269V cause constitutive activation of RHO with light-independent G protein coupling and impaired binding to arrestin. Differently, G90D and T94I are characterized by slow kinetics of RHO activation and deactivation. This study provides new evidence on the differential contribution of transmembrane α-helixes two and six to the interaction with intracellular transducers of RHO and mutations in these helixes result in a similar phenotype in patients but with distinct molecular effects.
Identifiants
pubmed: 39197629
pii: S0141-8130(24)05895-1
doi: 10.1016/j.ijbiomac.2024.135089
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135089Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest Authors A.B., S.DA., A.F., C.Z., B.B., F.F., L.C., V.K., I.M. and G.M. declare they have no competing financial interests. Author V.M. is shareholder of the company Mireca Medicines.